NYSE$BDX
Becton Dickinson & Co. · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported a decline in revenue due to decreased COVID-19 testing revenues, but experienced growth in base revenues and raised full year guidance.
BD reported a 6.0% decrease in revenue to $5.0 billion, driven by a significant decline in COVID-19 testing revenues. However, the company saw an 8.1% increase in base revenues. The company reported GAAP EPS of $2.28 and adjusted EPS of $3.64. BD raised its full year revenue and EPS guidance, reflecting confidence in its BD2025 strategy and strong base business performance.
- Revenue declined 6.0% as reported, primarily due to a decrease in COVID-only testing revenues.
- Base revenues grew 8.1%, driven by strong performance across all three segments.
- GAAP diluted EPS was $2.28, and adjusted diluted EPS was $3.64.
- The company raised full year revenue and EPS guidance.
Headline financials
Revenue & EPS history
BD · Revenue · Quarterly
$5B
Revenue by segment
BD · $2.53B total across 2 segments · Q4 2023
- BD Life Sciences$1.33B+3.3%52.5%
- BD Interventional$1.2B+9.7%47.5%
Forward guidance
The company raised its full year revenue and adjusted EPS guidance.
Tailwinds
- Fiscal year 2022 revenues are expected to be in the range of $19.55 billion to $19.75 billion.
- Base business currency-neutral revenue growth of 5.75% to 6.75% is expected.
- Approximately $450 million in COVID-19-only diagnostic testing revenues are assumed.
- Fiscal year 2022 adjusted diluted EPS to be $12.80 to $13.00.
Headwinds
- Foreign exchange would represent a headwind of approximately 125 basis points to total company revenue growth.
- Outlook reflects numerous assumptions about many factors that could affect its business, based on the information management has reviewed as of this date.
- Outlook continues to assume no extended major system-wide hospital restrictions on deferrable procedures related to the COVID-19 pandemic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.9%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-0.5%
Avg return
30 days after
38%
28 / 73 earnings
Positive
+8.9%
Q3 2025
Best reaction
-18.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -0.7% | -1.1% | +4.6% | |
| Q1 2026 | -1.3% | +6.5% | -1.2% | |
| Q4 2025 | +0.6% | +7.2% | +10.0% | |
| Q3 2025 | +8.9% | +13.1% | +11.6% | |
| Q2 2025 | -18.1% | -20.3% | -16.7% | |
| Q1 2025 | -6.3% | -5.3% | -5.3% | |
| Q4 2024 | -3.5% | -3.7% | -8.3% | |
| Q3 2024 | +0.3% | -2.3% | +0.6% | |
| Q2 2024 | +0.4% | +1.5% | -0.7% | |
| Q1 2024 | -0.7% | -0.1% | -1.5% | |
| Q4 2023 | -8.3% | -8.8% | -9.2% | |
| Q3 2023 | -2.0% | +1.8% | +0.8% | |
| Q2 2023 | -3.8% | -5.3% | -4.5% | |
| Q1 2023 | -3.3% | -0.4% | -6.7% | |
| Q4 2022 | +4.3% | +1.9% | +13.4% | |
| Q3 2022 | +3.8% | +4.2% | +3.2% | |
| Q2 2022 | +1.7% | -1.4% | -0.5% | |
| Q1 2022 | +4.7% | +7.7% | +7.3% | |
| Q4 2021 | -1.3% | -1.4% | -1.2% | |
| Q3 2021 | -5.4% | -6.3% | +1.2% | |
| Q2 2021 | -4.2% | -3.4% | -3.6% | |
| Q1 2021 | -2.4% | -2.6% | -5.5% | |
| Q4 2020 | -0.1% | +1.5% | +2.5% | |
| Q3 2020 | -9.5% | -10.0% | -17.4% | |
| Q2 2020 | -1.8% | +1.1% | -6.6% | |
| Q1 2020 | -13.7% | -10.3% | -16.4% | |
| Q4 2019 | -3.8% | -6.1% | -0.7% | |
| Q3 2019 | +3.5% | +7.6% | +9.4% | |
| Q2 2019 | -3.0% | -4.1% | +2.6% | |
| Q1 2019 | -1.7% | -2.0% | -0.2% | |
| Q4 2018 | -0.2% | +2.5% | +1.6% | |
| Q3 2018 | -1.1% | -0.8% | +4.7% | |
| Q2 2018 | -2.4% | -3.8% | -2.3% | |
| Q1 2018 | -1.3% | -3.4% | -0.6% | |
| Q4 2017 | +7.9% | +6.3% | +8.8% | |
| Q3 2017 | -1.9% | -2.1% | -0.9% | |
| Q2 2017 | -1.4% | -0.5% | +3.5% | |
| Q1 2017 | +0.2% | -0.1% | +3.2% | |
| Q4 2016 | +4.9% | +7.1% | -0.8% | |
| Q3 2016 | -1.2% | -0.9% | +0.9% | |
| Q2 2016 | +2.0% | — | — | |
| Q1 2016 | -4.9% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -2.8% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | +4.1% | — | — | |
| Q1 2013 | +3.2% | — | — | |
| Q4 2012 | -4.3% | — | — | |
| Q3 2012 | -1.1% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q4 2011 | -4.6% | — | — | |
| Q1 2012 | +1.2% | — | — | |
| Q3 2011 | -2.6% | — | — | |
| Q2 2011 | -1.0% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q4 2010 | +2.0% | — | — | |
| Q3 2010 | +1.6% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | +0.5% | — | — | |
| Q1 2010 | -1.4% | — | — | |
| Q4 2007 | -1.2% | — | — | |
| Q2 2009 | -1.2% | — | — | |
| Q4 2009 | -1.2% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q3 2008 | +2.5% | — | — | |
| Q4 2008 | +2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro